{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T09:39:47Z","timestamp":1767173987642,"version":"build-2238731810"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,7,22]],"date-time":"2022-07-22T00:00:00Z","timestamp":1658448000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,7,22]],"date-time":"2022-07-22T00:00:00Z","timestamp":1658448000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005343","name":"Fundaci\u00f3n IMSS","doi-asserted-by":"publisher","award":["Not applicable"],"award-info":[{"award-number":["Not applicable"]}],"id":[{"id":"10.13039\/501100005343","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Trials"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The 2020 pandemic of SARS-CoV-2 causing COVID-19 disease is an unprecedented global emergency. COVID-19 appears to be a disease with an early phase where the virus replicates, coinciding with the first presentation of symptoms, followed by a later \u2018inflammatory\u2019 phase which results in severe disease in some individuals. It is known from other rapidly progressive infections such as sepsis and influenza that early treatment with antimicrobials is associated with a better outcome. The hypothesis is that this holds for COVID-19 and that early antiviral treatment may prevent progression to the later phase of the disease.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Trial design: Phase IIA randomised, double-blind, 2 \u00d7 2 design, placebo-controlled, interventional trial.<\/jats:p>\n                    <jats:p>Randomisation: Participants will be randomised 1:1 by stratification, with the following factors: gender, obesity, symptomatic or asymptomatic, current smoking status presence or absence of comorbidity, and if the participant has or has not been vaccinated. Blinding: Participants and investigators will both be blinded to treatment allocation (double-blind).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>We propose to conduct a proof-of-principle placebo-controlled clinical trial of favipiravir plus or minus nitazoxanide in health workers, their household members and patients treated at the Mexican Social Security Institute (IMSS) facilities. Participants with or without symptomatic COVID-19 or who tested positive will be assigned to receive favipiravir plus nitazoxanide or favipiravir plus nitazoxanide placebo. The primary outcome will be the difference in the amount of virus (\u2018viral load\u2019) in the upper respiratory tract after 5 days of therapy. Secondary outcomes will include hospitalization, major morbidity and mortality, pharmacokinetics, and impact of antiviral therapy on viral genetic mutation rate. If favipiravir with nitazoxanide demonstrates important antiviral effects without significant toxicity, there will be a strong case for a larger trial in people at high risk of hospitalization or intensive care admission, for example older patients and\/or those with comorbidities and with early disease.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/clinicaltrials.gov\">ClinicalTrials.gov<\/jats:ext-link>\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04918927\">NCT04918927<\/jats:ext-link>\n                      . Registered on June 9, 2021.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13063-022-06533-0","type":"journal-article","created":{"date-parts":[[2022,7,22]],"date-time":"2022-07-22T08:04:30Z","timestamp":1658477070000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Favipiravir and\/or nitazoxanide: a randomized, double-blind, placebo-controlled trial of early therapy in COVID-19 in health workers, their household members, and patients treated at IMSS (FANTAZE)"],"prefix":"10.1186","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4486-3839","authenticated-orcid":false,"given":"Tania","family":"Smith","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlos","family":"Hoyo-Vadillo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akosua Agyeman","family":"Adom","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liliana","family":"Favari-Perozzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silke","family":"Gastine","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hakim-Moulay","family":"Dehbi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beatriz","family":"Villegas-Lara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eduardo","family":"Mateos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yessica Sara P\u00e9rez","family":"Gonz\u00e1lez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria D.","family":"Navarro-Gualito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alejandra S.","family":"Cruz-Carbajal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miguel A.","family":"Cortes-Vazquez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carolina","family":"Bekker-M\u00e9ndez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charmina","family":"Aguirre-Alvarado","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gisela","family":"Aguirre-Gil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lucero","family":"Delgado-Pastelin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew","family":"Owen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Lowe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph","family":"Standing","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jorge","family":"Escobedo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,7,22]]},"reference":[{"key":"6533_CR1","doi-asserted-by":"publisher","unstructured":"Cai Q, et al. Experimental treatment with Favipiravir for COVID-19: an open-label control study. Engineering. 2020. https:\/\/doi.org\/10.1016\/j.eng.2020.03.007.","DOI":"10.1016\/j.eng.2020.03.007"},{"key":"6533_CR2","doi-asserted-by":"publisher","unstructured":"Chen C, Huang J, Cheng Z, Zhang Y, et al. Favipiravir versus Arbidol for COVID-19: a randomized clinical trial. medRxiv. 2020. https:\/\/doi.org\/10.1101\/2020.03.17.20037432.","DOI":"10.1101\/2020.03.17.20037432"},{"key":"6533_CR3","doi-asserted-by":"publisher","unstructured":"Mahmoud DB, Shitu Z, Mostafa A. Drug repurposing of nitazoxanide: can it be an effective therapy for COVID-19? Genet Eng Biotechnol. 2020:18\u201335. https:\/\/doi.org\/10.1186\/s43141-020-00055-5.","DOI":"10.1186\/s43141-020-00055-5"},{"issue":"14","key":"6533_CR4","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.1007\/s10753-019-00994-3","volume":"42","author":"J Shou","year":"2019","unstructured":"Shou J, Kong X, Wamg X, et al. Tizoxanide inhibits inflammation in LPS-activated RAW264.7 macrophages via the Supression of NF-k and MAPK Activaction. Inflammation. 2019;42(14):1336\u201350. https:\/\/doi.org\/10.1007\/s10753-019-00994-3.","journal-title":"Inflammation"},{"issue":"11","key":"6533_CR5","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1186\/s13063-021-05139-2","volume":"22","author":"L-AK Brown","year":"2021","unstructured":"Brown L-AK, Freemantle J, Breuer J, et al. Early antiviral treatment in outpatients with COVID-19 (FLARE): a structured summary of a study protocol for a randomised controlled trial. Trials. 2021;22(11):193. https:\/\/doi.org\/10.1186\/s13063-021-05139-2.","journal-title":"Trials"},{"key":"6533_CR6","doi-asserted-by":"publisher","unstructured":"Lowe DM, Brown L-AK, Checkley A, et al. (FLARE):a randomised, double blind, 2X2 factorial placebo-controlled trial of early antiviral therapy in COVID-19. MedRxiv. 2022. https:\/\/doi.org\/10.1101\/2022.02.11.22270775.","DOI":"10.1101\/2022.02.11.22270775"},{"key":"6533_CR7","unstructured":"U.S. Department Of Health and Human Services, Common Terminology Criteria for Adverse Events (CTCAE). 2017. https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/docs\/CTCAE_v5_Quick_Reference_5x7.pdf."},{"key":"6533_CR8","unstructured":"Secretaria de Salud, NOM-220-SSA1-2016. Instalaci\u00f3n y operaci\u00f3n de la farmacovigilancia (Instalation and operation of Pharmacovigilance), Ciudad de M\u00e9xico. 2016. https:\/\/www.dof.gob.mx\/normasOficiales\/8356\/salud14_C\/salud14_C.html"},{"key":"6533_CR9","doi-asserted-by":"publisher","unstructured":"Goncalves A, Bertand J, Ke R, Comets E et. al., Timing of antiviral treatment initiation is critical to reduce SARS-CoV-2 viral load. CPT Pharmacometrics Syst Pharmacol. 2020;9(9):509\u201314. https:\/\/doi.org\/10.1002\/psp4.12543.","DOI":"10.1002\/psp4.12543"},{"key":"6533_CR10","doi-asserted-by":"publisher","unstructured":"Kim K, Ejima K, Ito Y, Iwanami S, et al. Modelling SARS-CoV-2 dynamics: implications for therapy. medRxiv. 2020. https:\/\/doi.org\/10.1101\/2020.03.23.20040493.","DOI":"10.1101\/2020.03.23.20040493"},{"key":"6533_CR11","unstructured":"Japanese Pharmaceuticals and Medical Devices Agency (PMDA), [I on the Deliberation Results (English versi\u00f3n) [internet]. https:\/\/www.pkda.go.jp\/files\/000210319.pdf, 2014."},{"key":"6533_CR12","doi-asserted-by":"publisher","first-page":"2173","DOI":"10.1056\/NEJMc1806941","volume":"1379","author":"C Ruis","year":"2018","unstructured":"Ruis C, Brown L, Roy S, Atkinson C, et al. Mutagenesis in Norovovirus in response to Favipiravir treatment. N Engl J Med. 2018;1379:2173\u20136. https:\/\/doi.org\/10.1056\/NEJMc1806941.","journal-title":"N Engl J Med"},{"key":"6533_CR13","volume-title":"Favipiravir tablets 200 mg, 400 mg (blister pack) pack insert global 1040662","author":"Strides Pharma Science Limited","year":"2020","unstructured":"Strides Pharma Science Limited. Favipiravir tablets 200 mg, 400 mg (blister pack) pack insert global 1040662; 2020."},{"key":"6533_CR14","doi-asserted-by":"publisher","first-page":"e1001967","DOI":"10.1371\/journal.pmed.1001967","volume":"113","author":"D Sissoko","year":"2016","unstructured":"Sissoko D, Laouenan C, Folkesson E, Lebing AM, et al. Experimental treatment with Favipiravir for Ebola virus disease (the JIKI trial): a Historiaclly controlled, single-arm proof o-of-concept Traial in Guinea. PLoS Med. 2016;113:e1001967. https:\/\/doi.org\/10.1371\/journal.pmed.1001967.","journal-title":"PLoS Med"},{"key":"6533_CR15","doi-asserted-by":"publisher","unstructured":"Rajoli R, Pertinez H, Arshad U, Box H, et al. Dose prediction for reporpusing nitazoxanide in SARS-CoV-2 treatment or chemoprophylaxis. MedRxiv. 2020. https:\/\/doi.org\/10.1101\/2020.05.01.20087130.","DOI":"10.1101\/2020.05.01.20087130"},{"key":"6533_CR16","unstructured":"Shin Poong Pharmaceutical Co. Ltd., \u201cPhase 2, Exploratory, Single Center, Randomized, Open Label, Adaptive Clinical Trial to Compare Safety and Efficacy of Four Different Experimental Drug Regimens to Standard of Care for the Treatment of Symptomatic Outpatients With COVID-19,\u201d NCT 04532931 clinicaltrials.gov, 31 Aug 2020. [En ligne]. Available: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04532931."}],"updated-by":[{"DOI":"10.1186\/s13063-023-07364-3","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2023,5,22]],"date-time":"2023-05-22T00:00:00Z","timestamp":1684713600000}}],"container-title":["Trials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-022-06533-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13063-022-06533-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-022-06533-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,22]],"date-time":"2023-05-22T08:05:10Z","timestamp":1684742710000},"score":1,"resource":{"primary":{"URL":"https:\/\/trialsjournal.biomedcentral.com\/articles\/10.1186\/s13063-022-06533-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,22]]},"references-count":16,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["6533"],"URL":"https:\/\/doi.org\/10.1186\/s13063-022-06533-0","relation":{},"ISSN":["1745-6215"],"issn-type":[{"value":"1745-6215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,22]]},"assertion":[{"value":"28 February 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 July 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 July 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 May 2023","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1186\/s13063-023-07364-3","URL":"https:\/\/doi.org\/10.1186\/s13063-023-07364-3","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Before initiation of the trial at any clinical site, the protocol, all informed consent forms, and any material to be given to the prospective participant will be submitted to the relevant EC for approval. Any subsequent amendments to these documents will be submitted for further approval. Before initiation of the trial at each additional clinical site, the same\/amended documents will be submitted for local permissions.The rights of the participant to refuse to participate in the trial without giving a reason must be respected. After the participant has entered the trial, the clinician remains free to give alternative treatment to that specified in the protocol, at any stage, if they assess this to be in the best interest of the participant. The reasons for doing so must be recorded. After randomisation the participant must remain within the trial for follow-up and data analysis according to the treatment option to which they have been allocated. However, the participant remains free to change their mind at any time about the protocol treatment and follow-up without giving a reason and without prejudicing their further treatment.Competent Authority Approvals.National Committee of Scientific Investigation (IRB00003566) on Feb 10th, 2020; and by the Federal Commission for the Protection against Sanitary Risks (COFEPRIS).Other Approvals.The protocol will be submitted by those delegated to do so to the Health Research Authority for national approval and relevant R&D departments of each participating site for review of local Trust Capacity and Capability. A copy of the local permissions (or other relevant approval as above) and of the consent form on local headed paper must be forwarded to the coordinating centre before participants are randomised to the trial.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate\u00a0{24}"}},{"value":"Integral Consent Form, version 4, dated November 12th, 2021, on page 13 states that:\u201cWhen the trial is completed, the researchers will share the trial data on an openly accessible website at the end of the trial to help other researchers studying COVID-19. You will not be identifiable on this website. The researchers may also share the trial data with commercial organisations such as drug companies, this data will not include your personal data will have a code number. We will also publish the results in a medical journal, so that other doctors can see them. Your identity and any personal details will be kept confidential. No named information about you will be published in any report of this trial.\u201dThe informed consent materials are in Spanish and are available from the corresponding author on request.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication\u00a0{32}"}},{"value":"The primary objective of this trial has been funded by Siegfried Rhein, S.A. de C.V. Other sources of financing may be included for the completion of the secondary outcomes.T.A.S. has received personal fees from Siegfried Rhein, S.A. de C.V.University College London. J.F.S. was supported by United Kingdom Medical Research Council (MRC) Fellowships (Grants M008665 and P014534)Nitazoxanide and nitazoxanide placebo were donated by Siegfried Rhein, S.A. de C.V.Favipiravir was donated by Strides Pharma Limited.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests\u00a0{28}"}}],"article-number":"583"}}